Aquestive Therapeutics (NASDAQ:AQST) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Aquestive Therapeutics (NASDAQ:AQST) announced its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01), FiscalAI reports. The firm had revenue of $7.56 million for the quarter, compared to the consensus estimate of $11.02 million.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST traded up $0.11 during trading on Tuesday, reaching $3.88. 2,033,973 shares of the stock were exchanged, compared to its average volume of 2,919,894. Aquestive Therapeutics has a 1-year low of $2.93 and a 1-year high of $6.85. The stock has a fifty day moving average of $4.64 and a two-hundred day moving average of $4.20. The firm has a market cap of $486.98 million, a price-to-earnings ratio of -5.97 and a beta of 1.49.

Insiders Place Their Bets

In other Aquestive Therapeutics news, insider Sherry Korczynski sold 8,750 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the sale, the insider owned 235,689 shares in the company, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 25,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $4.22, for a total transaction of $105,500.00. Following the transaction, the chief executive officer owned 627,317 shares in the company, valued at approximately $2,647,277.74. The trade was a 3.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 58,750 shares of company stock worth $271,675. 6.81% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

AQST has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 target price on shares of Aquestive Therapeutics in a research note on Thursday, September 10th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, October 16th. Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.60.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.